- Home
- ADUS vs IMCR Comparison
ADUS vs IMCR Comparison
Compare ADUS & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADUS
- IMCR
- Stock Information
- Founded
- ADUS 1979
- IMCR 2008
- Country
- ADUS United States
- IMCR United Kingdom
- Employees
- ADUS N/A
- IMCR N/A
- Industry
- ADUS Medical/Nursing Services
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ADUS Health Care
- IMCR Health Care
- Exchange
- ADUS Nasdaq
- IMCR Nasdaq
- Market Cap
- ADUS 2.1B
- IMCR 1.6B
- IPO Year
- ADUS 2009
- IMCR 2021
- Fundamental
- Price
- ADUS $112.08
- IMCR $33.99
- Analyst Decision
- ADUS Buy
- IMCR Buy
- Analyst Count
- ADUS 10
- IMCR 10
- Target Price
- ADUS $143.50
- IMCR $58.13
- AVG Volume (30 Days)
- ADUS 158.9K
- IMCR 422.6K
- Earning Date
- ADUS 08-04-2025
- IMCR 08-07-2025
- Dividend Yield
- ADUS N/A
- IMCR N/A
- EPS Growth
- ADUS 9.84
- IMCR N/A
- EPS
- ADUS 4.42
- IMCR N/A
- Revenue
- ADUS $1,211,561,000.00
- IMCR $333,581,000.00
- Revenue This Year
- ADUS $23.16
- IMCR $26.82
- Revenue Next Year
- ADUS $5.77
- IMCR $8.15
- P/E Ratio
- ADUS $25.39
- IMCR N/A
- Revenue Growth
- ADUS 11.38
- IMCR 25.75
- 52 Week Low
- ADUS $88.96
- IMCR $23.15
- 52 Week High
- ADUS $136.72
- IMCR $41.54
- Technical
- Relative Strength Index (RSI)
- ADUS 50.00
- IMCR 56.49
- Support Level
- ADUS $109.93
- IMCR $32.20
- Resistance Level
- ADUS $114.59
- IMCR $33.95
- Average True Range (ATR)
- ADUS 2.71
- IMCR 1.22
- MACD
- ADUS -0.50
- IMCR 0.06
- Stochastic Oscillator
- ADUS 36.76
- IMCR 95.84
About ADUS Addus HomeCare Corporation
Addus HomeCare Corp is engaged in the provision of in-home personal care services. It operates through the segments such as Personal care segment, which is a key revenue driver, provides non-medical assistance with activities of daily living, primarily to persons who are at risk of hospitalization or institutionalization, such as the elderly, chronically ill and disabled. The Hospice segment provides physical, emotional and spiritual care for people who are terminally ill and their families. Its Home health segment provides services that are primarily medical in nature to those individuals who may require assistance during an illness or after surgery.
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.